2011
DOI: 10.1111/j.1753-4887.2011.00400.x
|View full text |Cite
|
Sign up to set email alerts
|

Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonist

Abstract: Many clinical studies have been carried out to determine the health benefits of soy protein and the isoflavones contained in soy. S-equol is not present in soybeans but is produced naturally in the gut of certain individuals, particularly Asians, by the bacterial biotransformation of daidzein, a soy isoflavone. In those intervention studies in which plasma S-equol levels were determined, a concentration of >5-10 ng/mL has been associated with a positive outcome for vasomotor symptoms, osteoporosis (as measured… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
119
2
4

Year Published

2011
2011
2017
2017

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 175 publications
(126 citation statements)
references
References 112 publications
1
119
2
4
Order By: Relevance
“…Moreover, dietary soy, where genistein, daidzein, and equol were detected in serum samples, increased mammary epithelial cell proliferation of human subjects (25). Therefore, the association between equol production and cancer risk in humans remains to be adequately characterized (8,26,27). Overall, benefits from soy intake are associated with ER (ϩ) breast cancer, and the effect of equol or soy isoflavones on ER (Ϫ) breast cancers or established aggressive breast cancers are not well understood (5,28,29).…”
mentioning
confidence: 99%
“…Moreover, dietary soy, where genistein, daidzein, and equol were detected in serum samples, increased mammary epithelial cell proliferation of human subjects (25). Therefore, the association between equol production and cancer risk in humans remains to be adequately characterized (8,26,27). Overall, benefits from soy intake are associated with ER (ϩ) breast cancer, and the effect of equol or soy isoflavones on ER (Ϫ) breast cancers or established aggressive breast cancers are not well understood (5,28,29).…”
mentioning
confidence: 99%
“…Nem minden ember szervezete képes viszont az equol szinté-zisére. Az ázsiai országokban a populáció 80%-a, Euró-pában és Észak-Amerikában csupán a lakosság negyede equoltermelő, tehát az egyének között jelentős különb-ség van a metabolizmusban [20].…”
Section: öSszefoglaló Közleményunclassified
“…A daidzein metabolizmusának lépései [20] ÖSSZEFOGLALÓ KÖZLEMÉNY Az izoflavonoidok 25 mg dózisban már szignifikánsan csökkentették a depressziós tüneteket és az alvászavart is, emellett a Menopauza Skála értékeiben is szignifikáns javulást regisztráltak [24].…”
Section: áBraunclassified
“…Later, phyto-oestrogen research extended to human medicine, particularly regarding the possible health benefits of the soy isoflavones glycitein, genistein, and daidzein and its metabolite equol. Currently, equol is the most studied isoflavone metabolite in human medicine (Lampe, 2010;Jackson et al, 2011).…”
Section: Introductionmentioning
confidence: 99%